drugset / Trial / NCT05749432
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The study will be conducted in about 51 participants in total. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor efficacy of Hemay181 in patients with advanced solid tumors.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2026-01-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hemay181 | Unknown | 4.5 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 9 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 18 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 36 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 60 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 90 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 120 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 150 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 180 mg/m2 | Intravenous |
| Subject | Hemay181 | Unknown | 210 mg/m2 | Intravenous |